This Directive should provide for the right for a patient to receive any medicinal product authorised for marketing in the Member State of treatment, even if the medicinal product is not authorised for marketing in the Member State of affiliation, as it is an indispensable part of obtaining effective treatment in another Member State. Nothing should oblige a Member State of affiliation to reimburse an insured person for a medicinal product prescribed in the Member State of treatment, where that medicinal product is not among the benefits provided to that insured person by the statutory social security system or national health system in the Member State of affiliation.
Recital 36, Directive (EU) 2011/24
In forcesince 9 Mar 2011cited 1×
Judgment of the Court (Fifth Chamber) of 18 September 2019. VIPA Kereskedelmi és Szolgáltató Kft. v Országos Gyógyszerészeti és Élelmezés-egDecision
That interpretation, resulting from the context of Article 11(1), is supported by the objectives pursued by Directive 2011/24. According to Article 1(1) and (2) of that directive, read in the light of recitals 10 and 11 thereof, that …
18 Sep 2019 · 62018CJ0222